Limits...
Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.

Gomes FV, Guimarães FS, Grace AA - Int. J. Neuropsychopharmacol. (2014)

Bottom Line: Evidence from studies in animals has indicated that a combination of repeated pubertal cannabinoid administration with either neonatal prefrontocortical lesion, isolation rearing, or chronic NMDA receptor antagonism administration induces enhanced schizophrenia-like behavioral disruptions.The effects of adolescent exposure to CB1 receptor agonists, however, have not been tested in a developmental disruption model of schizophrenia.Adult rats were tested for attentional set-shifting task and locomotor response to amphetamine, which was compared with in vivo recording from ventral tegmental area (VTA) dopamine (DA) neurons.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Brazil (Drs Gomes and Guimarães); Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Gomes and Guimarães); Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, A210 Langley Hall, Pittsburgh, PA 15260 (Dr Grace). gomesfv@usp.br.

Show MeSH

Related in: MedlinePlus

Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4368886&req=5

Figure 1: Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).

Mentions: As adults, the animals were submitted to the behavioral (PD85–PD100) and electrophysiological tests (PD100–PD125; Figure 1). The WIN dose and the experimental design were based on previous studies (Schneider and Koch, 2002, 20032005, 2007; Schneider et al., 2005; Schneider et al., 2008; Du and Grace, 2013; Zimmerman et al., 2013). All experiments were performed with investigators blinded to treatment.


Effects of pubertal cannabinoid administration on attentional set-shifting and dopaminergic hyper-responsivity in a developmental disruption model of schizophrenia.

Gomes FV, Guimarães FS, Grace AA - Int. J. Neuropsychopharmacol. (2014)

Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4368886&req=5

Figure 1: Experimental design. Pregnant rats were administered MAM or saline on GD 17. Rats from each group received either i.p. administration of the CB1/2 receptor agonist WIN55,212-2 (1.2mg/kg) or Veh during PD40 to PD65. These rats were used for behavioral (attentional set-shifting task and amphetamine-induced hyperlocomotion) and electrophysiology tests as adults (PD > 85).
Mentions: As adults, the animals were submitted to the behavioral (PD85–PD100) and electrophysiological tests (PD100–PD125; Figure 1). The WIN dose and the experimental design were based on previous studies (Schneider and Koch, 2002, 20032005, 2007; Schneider et al., 2005; Schneider et al., 2008; Du and Grace, 2013; Zimmerman et al., 2013). All experiments were performed with investigators blinded to treatment.

Bottom Line: Evidence from studies in animals has indicated that a combination of repeated pubertal cannabinoid administration with either neonatal prefrontocortical lesion, isolation rearing, or chronic NMDA receptor antagonism administration induces enhanced schizophrenia-like behavioral disruptions.The effects of adolescent exposure to CB1 receptor agonists, however, have not been tested in a developmental disruption model of schizophrenia.Adult rats were tested for attentional set-shifting task and locomotor response to amphetamine, which was compared with in vivo recording from ventral tegmental area (VTA) dopamine (DA) neurons.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Medical School of Ribeirão Preto, University of São Paulo, Brazil (Drs Gomes and Guimarães); Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Gomes and Guimarães); Departments of Neuroscience, Psychiatry and Psychology, University of Pittsburgh, A210 Langley Hall, Pittsburgh, PA 15260 (Dr Grace). gomesfv@usp.br.

Show MeSH
Related in: MedlinePlus